ArticleOpen forum infectious diseases2016
Miltefosine for Mucosal and Complicated Cutaneous Old World Leishmaniasis: A Case Series and Review of the Literature.
Article in Open forum infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Tonsillar Leishmaniasis: A Rare Clinical Entity Mimicking Malignancy in the Oropharynx - A Case Series from Northeastern Italy.Head and neck pathology · 2025Article
- A rare case of lingual mucosal leishmaniasis caused by reactivation of Leishmania infantum infection.BMC infectious diseases · 2025Article
- Tolerability and Safety of Miltefosine for the Treatment of Cutaneous Leishmaniasis.Tropical medicine and infectious disease · 2024Article
- Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients.PLoS neglected tropical diseases · 2021Observational
- Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.Pathogens (Basel, Switzerland) · 2021Article
- Miltefosine for the treatment of cutaneous leishmaniasis-A pilot study from Ethiopia.PLoS neglected tropical diseases · 2021Article
- Cutaneous Leishmaniasis Treated with Miltefosine: A Case Series of 10 Paediatric Patients.Acta dermato-venereologica · 2020Article
- Case Report: Mucosal Leishmaniasis in New York City.The American journal of tropical medicine and hygiene · 2020Article
- Autochthonous Cases of Mucosal Leishmaniasis in Northeastern Italy: Clinical Management and Novel Treatment Approaches.Microorganisms · 2020Article
- Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.PLoS neglected tropical diseases · 2019Observational
- Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.PLoS neglected tropical diseases · 2017Article
- Case Report: Old World Mucosal Leishmaniasis: Report of Five Imported Cases to the Hospital for Tropical Diseases, London, United Kingdom.The American journal of tropical medicine and hygiene · 2017Article
- Phlebotomine sand fly-borne pathogens in the Mediterranean Basin: Human leishmaniasis and phlebovirus infections.PLoS neglected tropical diseases · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complicated Old World cutaneous leishmaniasis (OWCL) and Old World mucosal leishmaniasis (OWML) constitute an indication for systemic treatment. To date, there no controlled clinical studies that compare treatment options for these diseases. We compiled a case series of 24 cases successfully treated with miltefosine. We conclude that oral miltefosine is an effective treatment option for both OWCL and OWML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.